Overview

Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
0
Participant gender:
All
Summary
This is a Phase 2 study designed to assess the ability of RP-G28 to improve lactose digestion and tolerance.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ritter Pharmaceuticals, Inc.
Criteria
Inclusion Criteria:

- Male and female subjects. Female subjects must be non-pregnant and non-lactating.

- 18 to 64 years of age inclusive at Screening

- Current or recent history of intolerance to milk and other dairy products

- Acceptable Baseline Lactose Intolerance Symptom Scores

- Acceptable Result on Baseline Hydrogen Breath Test

- Subjects must agree to refrain from all other treatments and products used for lactose
intolerance during the study

Exclusion Criteria:

- Disorders known to be associated with abnormal GI motility

- History of surgery that alters the normal function of the gastrointestinal tract

- Past or present; organ transplant, chronic pancreatitis, pancreatic insufficiency,
symptomatic biliary disease, Celiac disease, inflammatory bowel disease (IBD),
ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS)

- Active gastric or duodenal ulcers or history of severe ulcers

- Diabetes mellitus (type 1 or type 2)

- Congestive Heart Failure

- History of Human Immunodeficiency Virus (HIV), Hepatitis B or C

- Use of concurrent therapy(ies) for symptoms of lactose intolerance

- Uncontrolled BP defined as sitting systolic blood pressure (SBP) ≥160 mmHg or
diastolic blood pressure (DBP) ≥95 mmHg at Visit 1

- History of ethanol abuse in the past 12 months

- History of drug abuse within 12 months

- History or presence of malignancy within the past 5 years (except basal cell or
squamous cell carcinoma removed from a sun-exposed area)

- Use of any investigational drug or participation in any investigational study within
30 days prior to Screening